Layfferon, 3 mln.mes 5 pcs

Lyfferon has antiviral, antitumor and immunomodulatory activity.

Long-term use of the drug in individuals may cause antibodies to interferon, resulting in decreased efficacy.

Indications

Adults in the complex therapy:

Composition

1 ampoule contains:

Active substance:

interferon alpha-2b human recombinant 3 millionIU;

Auxiliary substances:

sodium chloride,

sodium hydrophosphate dodecahydrate,

Sodium dihydrophosphate dihydrate,

D-sorbitol,

Urea,

reopolyglucin.

How to take, the dosage

Intravenous injection. The average daily dose is 1 million ME/day.

Perifocal injection

In cases of basal cell and squamous cell cancer, keratoacanthoma the drug is administered under the lesion 1 million ME 1 time daily for 10 days. In case of pronounced local inflammatory reactions injection under the lesion site is carried out after 1-2 days. At the end of the course cryodestruction is performed if necessary.

Lyfferon subconjunctival injection

In cases of stromal keratitis and kerato-iridocyclitis subconjunctival injections of Lifferon in the dose of 60,000 ME (in the volume of 0.5 ml) are indicated daily or every other day depending on the severity of the process. The injections are performed under local anesthesia with 0.5% dicaine solution. The course of treatment is from 15 to 25 injections.

Local administration

In conjunctivitis and superficial keratitis 2 drops of Laifferon solution are applied to the conjunctiva of the affected eye 6-8 times a day. As inflammation disappears the number of instillations is reduced to 3-4 times a day. The course of treatment is 2 weeks.

Interaction

In concomitant use interferon alfa-2b may decrease the activity of microsomal liver enzymes of cytochrome P450 system and, therefore, affect the metabolism of cimetidine, phenytoin, dipyridamole, theophylline, diazepam, propranololol, warfarin, some cytostatics.

The drug may increase the neurotoxic, myelotoxic or cardiotoxic effects of drugs previously or simultaneously prescribed.

Special Instructions

Full or partial remission can be obtained in laryngeal papillomatosis, but the use of the drug is recommended preferably to prevent recurrences with prior surgical removal of the tumor. In acute condyloma and plantar warts, complete clinical and histological efficacy was obtained in 60% of cases. In subacute hepatitis, intraperitoneal and intramuscular injection significantly increases the likelihood of survival.

In acute hepatitis B type use of the preparation is recommended in case if bilirubin concentration or activity of “liver enzymes” remains high 4 weeks after disease onset; if hepatitis B virus surface antigen test is positive 5 weeks after disease onset; if risk factors such as immunodeficiency, taking immunosuppressive medications due to a concomitant illness, heavy physical activity, or taking ethanol in the prodromal or initial period of the disease appear.

The use of the drug for treatment of adults with active chronic hepatitis B with a positive test for surface antigen of hepatitis B virus gave 50% seroconversion in 6 months after 4-month regimen. When treating children with the drug we received 40% of seroconversion to hepatitis B surface antigen in 6 months after the start of treatment. it is especially effective in immunosuppressed patients with chronically active hepatitis B.

In chronic hepatitis C usage of the preparation normalizes ALT serum activity in 50% of cases, though half of them have disease relapse after discontinuation of the treatment. Administration of the drug in shingles reduces the treatment period from 7-10 days to 3-4 days. Disappearance of pain usually occurs after 2-3 days (instead of 5-7 days). Use of the drug prevents the development of post-herpetic neuritis.

After long-term treatment of asymptomatic HIV carriers (3-52 months) with 3 million IU 3 times a week v/m, a delay of 40 months in the onset of AIDS-associated symptoms was observed. In this group of patients, the incubation period of the disease lengthened by 50 months; fewer comorbidities and complications were observed, and there was no significant decrease in the absolute number and percentage of CD4+ lymphocytes. Early administration of interferon alfa, within the first 72 hours after the onset of Dengue virus fever, can prevent the occurrence of severe hemorrhagic complications and shock.

The drug causes significant clinical regression or stabilization of the disease in hairy cell leukemia, even if the patient has previously undergone splenectomy. In chronic myeloleukemia it is possible to achieve remission with interferon monotherapy, but since the drug has a slower effect than cytostatics, its use is recommended to maintain remission previously achieved through chemotherapy.

The use of the drug prevents relapses for a year or more, extends life expectancy and significantly reduces the ratio of Philadelphia chromosome positive cells. When treating patients with non-Hodgkin’s lymphoma it is recommended to use the drug after obtaining remission with chemotherapy and radiation therapy, at that the relapse rate significantly decreases and the survival period increases.

The drug should be used immediately after dissolution. Water should be added gently to the vessel wall, avoiding foaming. The drug should not be used if precipitate, turbidity, or discoloration occurs after dissolution. Although the drug has not been shown to have a direct cardiotoxic effect, it is possible that side effects such as elevated body temperature, chills, and malaise may exacerbate CVD disease. Use of various interferon alfa has been associated with an increased risk of allergic or autoimmune manifestations, such as bronchospasm, drug lupus, psoriasis, atopic dermatitis, or thyroiditis. Although these phenomena have occurred exceptionally rarely, caution should be exercised when a patient has a history of these diseases. The adverse reactions caused by taking the drug are reversible.

In case they occur, it is reasonable to reduce the dose or interrupt treatment and take appropriate measures according to the patient’s condition. Although side effects decrease during treatment with the drug, if they persist or reappear, the patient should be closely monitored.

Tests have not shown any teratogenic effect or effect on fertility. Studies on the efficacy and safety of use in pregnancy have not been conducted. Taking this into consideration the physician should conduct a risk-benefit analysis before prescribing the drug in each specific case.

The side effects were similar to those seen in adults and consisted mainly of increased body temperature and general malaise. No growth disturbances or psychosomatic development were noted, even after many months of continuous treatment with the drug.

Contraindications

Side effects

Body effects in general: during parenteral administration chills, fever, fatigue, headache, malaise, flu-like syndrome are possible. These side effects are partially controlled with paracetamol.

Overlooking organ: Conjunctival infection, mucosal hyperemia, single follicles, lower vault conjunctival edema are possible when used topically.

Laboratory parameters: leukopenia, lymphopenia, thrombocytopenia, ALT and ALP activity increase. For timely detection of these deviations during therapy general clinical blood tests should be repeated every 2 weeks, and biochemical – every 4 weeks. As a rule, these changes are usually minor, asymptomatic and reversible.

In case of severe adverse reactions or persistence for a long time, temporary dose reduction (if platelet count is less than 50,000/μL, absolute neutrophil count is less than 750/μL) or discontinuation of therapy (if platelet count is less than 25,000/μL, absolute neutrophil count is less than 500/μL) is allowed.

Pregnancy use

The drug is contraindicated in pregnancy.